New oral GLP-1RA orforglipron comparable to semaglutide for weight loss
Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in… read more.
Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in… read more.
A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out who might develop… read more.
Type 2 diabetes patients with cognitive impairment appear to be at increased risks of stroke, heart attack or death compared with non-diabetic patients. Researchers reported their findings on… read more.